ESMO Events 2026

Meetingsopens in new tab/window | ESMOopens in new tab/window

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the theme of the meeting:

ESMO Gastrointestinal Cancers Congress 2026opens in new tab/window

This key meeting will gather world-renowned specialists, clinical researchers, and medical professionals who are at the forefront of progress in the prevention, diagnosis, and treatment of gastrointestinal cancers.

With an engaging scientific agenda that includes expert-led discussions, multidisciplinary tumour boards, debates on clinical controversies, and cutting-edge research presentations, participants will gain valuable insights into the evolving landscape of GI oncology.

Topics will span the full continuum of care, from early detection and biomarker-driven therapies to innovations in systemic treatment and patient quality of life.

Designed to foster knowledge exchange and collaboration, the congress offers numerous opportunities to connect with peers, discuss real-world challenges, and share perspectives on advancing GI cancer care.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trialopens in new tab/window R. Liu, J. Zhao, R. Zhang, B. Liu, Y. Liu, S. Li, Y. Chen, H. Yang, Z. Liu, Z. Li, Y. Qin, M. Huang, Y. Ba, H. Zhang, Y. Qu, Y. Du, T. Deng, M. Yang, X. Hou, C. Liu, F. Ning, Y.P. Liu, X. Wu, Y. Xie, Y. An, K. Zou, L. She, J. Xu

• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upopens in new tab/window C. Cremolini, M. Chalabi, E. Elez, M. Fassan, M. Gelli, D. Goéré, D.P. Modest, C. Montagut, P. Osterlund, J. Ricke, J. Seligmann, J. Taieb, T. Yoshino, L. Wyrwicz, M. Ducreux, on behalf of the ESMO Guidelines Committee

ESMO Open

• Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studiesopens in new tab/window S.B. Maron, R.-H. Xu, Z.A. Wainberg, S.Y. Rha, Y. Zhang, F. Pietrantonio, S.C.S. Oliveira, Y. Li, M.-H. Chen, K. Korphaisarn, E. Elimova, C.A. Calderon, F.V. Herpe, W.P. Yong, T.M. Dos Santos, M. Tan, K. Isse, R.E. Yanes, K. Shitara

• Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathwayopens in new tab/window Y. Matsubara, M. Wakabayashi, W. Okamoto, T. Kato, T. Esaki, K. Kato, Y. Komatsu, T. Masuishi, T. Nishina, H. Bando, T. Misumi, M. Fukui, S. Matsuda, Y. Ikeda, J. Malato, K. Schulze, R. Price, A. Sato, T. Yoshino, Y. Nakamura

Immuno-Oncology and Technology

• Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of careopens in new tab/window E. Bengala, D. Santini, V. Picone

• A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE)opens in new tab/window I.M. Chen, S. Theile, K. Madsen, J.S. Johansen, T. Lorentzen, A. Toxværd, E. Høgdall, I.M. Svane, D. Nielsen

ESMO Gastrointestinal Oncology

• A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trialopens in new tab/window D. Okemoto, D. Kotani, M. Nakamura, K. Sato, Y. Kubo, T. Kadota, S. Mishima, S. Sakashita, T. Hashimoto, H. Bando, M. Wakabayashi, M. Rabinowitz, M.C. Liu, A. Jurdi, T. Yamaguchi, H. Nishikawa, K. Shitara, T. Yano, T. Kojima, Takeo Fujita

• Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal canceropens in new tab/window M. Fakih, S. Gill, K. Sampat, D.L. Chan, G. Fisher, M. Cruz-Correa, H.-J. Lenz, P. Garcia-Alfonso, F. Forget, S. Lonardi, J. Krauss, E. Chen, A. Cubillo Gracian, Y. Liu, N. van Buuren, J. Shao, M. Dong, A. Chen, M. Tejani, J.R. Hecht

ESMO Real World Data and Digital Oncology

• Prognostic impact of clinical factors in MSI-H/dMMR gastrointestinal tumors treated with immune checkpoint inhibitors: results from a multicenter real-world studyopens in new tab/window N. Martinez-Lago, A. Cousillas, P. Jara, M. Reboredo, P.G. Villarroel, M. Covela, R. Jimeno, S. Agraso, P. Sampedro, A. Carral, M. Perez, A. Garrido, J. de la Cámara Gómez, N. De Dios Alvarez, A. Fernandez-Montes, C. Lopez

• Liquid biopsies using circulating tumor DNA for surveillance of gastrointestinal cancers in Hispanics: first real-world data reportopens in new tab/window C. Cardona-De Jesús, H. Centeno-Girona, F. Garau-Rolón, H. Melero-Rodríguez, I. Alicea, M. Cruz-Correa

ESMO Rare Cancers

• The value of MMR characterization and efficacy of checkpoint inhibitor in patients with small-bowel adenocarcinomas: a retrospective real-world cohort studyopens in new tab/window R.H. Døssing, J.J.A. Bromann, K. Seierøe, E. Høgdall, T.S. Poulsen, J.H.V. Schou, D. Høgdall

ESMO affiliated journals

• Expanding the therapeutic Frontier: Liver transplantation for unresectable colorectal liver metastasesopens in new tab/window Alex B. Munster, Umair Mahmood, Heather Fuller, Hajun Seo, Jamie Murphy, Krishna Menon, Charles Imber, Chetan Bhan, Khurum Khan

• Prognostic role of postoperative circulating tumor DNA in metastatic colorectal cancer treated with curative intent: A systematic review and meta-analysisopens in new tab/window Claudia Cardone, Sergio Facchini, Bruna de Oliveira Ascef, Antonino Cassata, Alfonso De Stefano, Paolo Chiodini, Antonio Avallone

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.